X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the agreement, medac receives an exclusive license to commercialize oNKord® (GTA002) in the EU, the UK and further European countries for acute myeloid leukemia (AML) and multiple myeloma (MM) patients.
Lead Product(s): GTA002,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: oNKord
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Medac
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 01, 2022
Details:
oNKord (allogeneic ex vivo-generated NK cells) is immunotherapy product in clinical development. It gets produced in a closed system in Glycostem’s state-of-the-art and GMP licensed production facility, from which it can be distributed globally.
Lead Product(s): Allogeneic Ex-vivo Generated NK cells,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: oNKord
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 13, 2022
Details:
WiNK is a two-stage phase I/IIa trial to study the safety and efficacy of oNKord®, an off-the-shelf, ex. vivo-cultured allogeneic NK cell preparation, AML patients who are in complete morphologic remission with no strong indication for hematopoietic stem cell transplantation.
Lead Product(s): oNKord
Therapeutic Area: Oncology Product Name: oNKord
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 20, 2020
Details:
ONKord® is Glycostem’s first-generation off-the-shelf Natural Killer (NK) cellular immunotherapy product. Over the coming months, AML patients will receive this form of treatment as part of a phase I-IIa (pivotal) trial in AML.
Lead Product(s): oNKord
Therapeutic Area: Oncology Product Name: oNKord
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2020
Details:
Glycostem will assess their NK cells using LUMICKS’ z-Movi to gain new insights into the cell avidity and functional properties of their cells. Avidity is a new parameter that is crucial to understand immune cells better and choose the most potent ones for immunotherapy.
Lead Product(s): CAR-NK cells
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: LUMICKS
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 30, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
